What is Freenome, Inc.'s (FRNM) StockRank?

MoatMap's StockRank for Freenome, Inc. (FRNM) is 18/100, with a Strong Sell signal. This is a composite score combining Quality (17), Value (24), and Momentum (60) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Freenome, Inc. have an economic moat?

Freenome, Inc. (FRNM) has a Quality factor score of 17/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Freenome, Inc. a buy, hold, or sell?

MoatMap's current signal for Freenome, Inc. (FRNM) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Freenome, Inc. in?

Freenome, Inc. (FRNM) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

FRNM

Strong SellHot Air

Freenome, Inc. · Healthcare · United States · $1.6B · Avg Vol: $13M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

—

D/E

7.8x

Dividend %

—

COMPANY DESCRIPTION

Freenome is a healthcare diagnostics company developing early-detection tests for cancer through its proprietary multi-omics platform. Its moat is built on high-level R&D in blood-based screening, positioning the firm at the forefront of non-invasive diagnostics.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	2.9M	30.4M	35.4M	102.4M	113.8M	93.5%
EPS	-2.65	-2.07	-2.07	-3.54	-2.40	—
Shares	106.1M	106.1M	107.4M	—	—	—
Debt	206.5M	311.6M	311.5M	—	—	—
Equity	-1.1B	-1.3B	—	—	—	—
Op CF	-196.4M	-110.7M	-108.1M	—	—	—
Inv CF	-52.8M	21.4M	—	—	—	—
Fin CF	264.0M	100.8M	—	—	—	—

Loading 1Y...

PRICE (1Y)+48.0%

SMA 50SMA 200

$14.79

RSI (14)

60.9

52W High

$17.17

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-46.4%17.0

ROE

—N/A

GP/Assets

-34.6%2.4

Op. Margin

-2867.5%4.7

FCF/Assets

-26.0%16.3

Piotroski

668.6

Int. Cover

-50.0x5.8

D/E Ratio

7.83x1.4

Current Ratio

1.05x12.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-16.1x25.0

P/FCF

—N/A

P/B

-0.3x25.0

P/S

49.5x9.5

Div Yield

—N/A

Momentum

52W High %

86%79.9

RS 6M

18%80.8

SMA 50/200

1.04x65.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-16%15.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.6B

P/E (Forward)

-6.8x

Gross Margin

93.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FRNM are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
FRNM	Freenome, Inc.(you)	$1.6B	18	Strong Sell
PSNL	Personalis, Inc.	$1.8B	24	Sell
WGS	GeneDx Holdings Corp.	$2.6B	24	Sell
GRAL	GRAIL, Inc.	$3.6B	28	Sell
OPK	OPKO Health, Inc.	$1.1B	38	Hold
CSTL	Castle Biosciences, Inc.	$1.0B	39	Hold
MYGN	Myriad Genetics, Inc.	$302M	21	Sell
NEO	NeoGenomics, Inc.	$2.3B	47	Hold
ADPT	Adaptive Biotechnologies Corporation	$4.0B	38	Hold
RDNT	RadNet, Inc.	$5.9B	34	Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%

Freenome, Inc. (FRNM): Stock Score Summary

Freenome, Inc. (FRNM) has a MoatMap StockRank of 18/100 based on Quality (17/100), Value (24/100), and Momentum (60/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$14.79
Market Cap	$1.6B
P/E (Forward)	-6.80
Price/Book	-0.31
Return on Invested Capital	-46.4%
Debt/Equity	7.83x
Gross Margin	93.6%
Operating Margin	-2867.5%
Revenue Growth	106.5%
Free Cash Flow	$-132M

Freenome, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Freenome, Inc.’s (FRNM) StockRank?: MoatMap’s StockRank for Freenome, Inc. (FRNM) is 18/100, with a Strong Sell signal. It is a composite of Quality (17), Value (24), and Momentum (60) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Freenome, Inc. have an economic moat?: Freenome, Inc. (FRNM) has a Quality factor score of 17/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Freenome, Inc. a buy, hold, or sell?: MoatMap’s current signal for Freenome, Inc. (FRNM) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Freenome, Inc. in?: Freenome, Inc. (FRNM) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).